Gilead Pays Vir $90M Upfront in Deal Worth Up to $1.9B

Gilead Sciences has licensed rights to three new cancer drug candidates from Vir Biotechnology. Vir announced the deal on October 14, 2026. Vir will discover the drugs, which are masked T-cell engagers aimed at solid tumours, and Gilead will take them forward.

What happened

Under the agreement, Vir will discover, design and optimize three candidates using its PRO-XTEN dual-masked technology. Each one will target an antigen linked to solid tumours. Gilead holds an exclusive license to nominate and advance the candidates. It will run later development, manufacturing and commercialization.

The financial terms, according to Vir:

• Upfront: $90 million, made up of $65 million in cash and a $25 million equity investment at a 30% premium.
• Near term: up to $45 million in preclinical milestones, for up to $135 million including the upfront.
• Later: up to $1.74 billion in development, regulatory and commercial milestones.
• Royalties: tiered, from the high single digits to the low double digits on net sales.

Fierce Biotech put the total potential value at up to $1.9 billion. Vir CEO Marianne De Backer told the outlet that the three targets were ones Vir was not interested in pursuing on its own.

Why it matters

Vir says its masking keeps each engager switched off until it reaches the tumour. There, tumour-specific proteases remove the mask. That activates the engager so T cells can kill cancer cells. The company says the goal is to limit toxicity, widen the therapeutic index and possibly allow less frequent dosing.

This is the second partnership built on the PRO-XTEN platform. The first was with Astellas, formed in February. Astellas paid $315 million upfront for VIR-5500, which has FDA Fast Track designation in prostate cancer. De Backer told Fierce the partners plan to take it into phase 3 next year.

Gilead has signed several cancer deals this year. Fierce listed its $7.8 billion Arcellx acquisition among them. It also pointed to clinical setbacks for Gilead's Trodelvy, most recently in first-line non-small cell lung cancer.

What it means for people in the industry

The work splits along clear lines. Early discovery stays with Vir, which uses an AI-enabled platform called dAIsY to tune its engagers. Gilead takes over once it nominates a candidate. The announcements did not mention hiring or site plans.

A few things are worth watching. Vir expects phase 1 dose-escalation data for its own HER2 engager, VIR-5818, later this year. De Backer also said there is room for more deals in masked T-cell engagers.

See open pharma jobs in the US and Canada

Sources

• Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN Dual-masked T-cell Engagers for Solid Tumors, Vir Biotechnology
• Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs, Fierce Biotech